FrancophonIA/ELRC3.0 huggingface dataset:
English: - Lopinavir/Ritonavir Mylan contains the active substances lopinavir and ritonavir.
Maltese: - Lopinavir/ritonavir Mylan fih is-sustanzi attivi lopinavir u ritonavir.
English: Increased creatine phosphokinase (CPK), myalgia, myositis, and rarely, rhabdomyolysis have been reported with protease inhibitors, particularly in combination with nucleoside reverse transcriptase inhibitors.
Maltese: Gew rapurtati żieda fi creatine phosphokinase (CPK), mijalġja, mijożite u rarament rabdomijoliżi, ma inibituri tal-proteaż, speċjalment f'kombinazzjoni ma inibituri ta' nucleoside reverse transcriptase.
English: Antibiotic
Maltese: Opioids
English: HIV-1 isolates with reduced susceptibility to lopinavir have been selected in vitro.
Maltese: L-iżolati ta' HIV-1 b'suxxettibilità mnaqqsa għal lopinavir, ġew magħżula in vitro.
English: In general, rebound isolates either retained (if cross-resistant at baseline) or developed significant cross-resistance to indinavir, saquinavir and atazanavir.
Maltese: Ġeneralment, iżolati li marru lura, jew żammew (jekk kienu cross-resistant fil-linja bażi) jew żviluppaw cross-resistance sinifikanti għal indinavir, saquinavir u atazanavir.
English: Trazodone: AUC: ↑ 2.4-fold
Maltese: AUC: ↑ 2.4-darbiet
English: Hepatitis C virus direct acting antivirals
Maltese: Antivirali li jaġixxu b'mod dirett fuq ilvirus tal-epatite Ċ
English: The mean steady-state trough concentration prior to the morning dose was 5.5 ± 5.4 μg/ml.
Maltese: Il medja tal-konċentrazzjoni minima fl-istat fiss qabel id-doża ta ' filgħodu kienet ta ' 5.5 ± 5.4 μg/ml.
English: AUC: ↓ 34% Cmax: ↓ 30% Cmin: ↓ 43%
Maltese: ↓ 34% Cmax: ↓ 30% Cmin: ↓ 43%
English: Co-administration of ibrutinib and Lopinavir/Ritonavir Mylan may increase ibrutinib exposure which may increase the risk of toxicity including risk of tumor lysis syndrome.
Maltese: Ko-amministrazzjoni ta' ibrutinib u Kaletra jista' jżid l-espożizzjoni ta' ibrutinib li jista' jżid ir-riskju ta' tossiċità inkluż ir-riskju ta' sindromu tal-lisi tat-tumur.
English: Due to induction of lamotrigine glucuronidation Valproate: ↓
Maltese: Lamotrigine u Valproate Lamotrigine:
English: Cardiac events have been reported with lopinavir/ritonavir in preclinical studies; therefore, the potential cardiac effects of lopinavir/ritonavir cannot be currently ruled out (see sections 4.8 and 5.3).
Maltese: Fl-istudji ta' qabel l-użu kliniku, ġew irrappurtati effetti kardijaċi meta ngħata lopinavir/ritonavir; għalhekk, l-effetti kardijaċi potenzjali ta' lopinavir/ritonavir ma jistgħux jiġu esklużi għalissa (ara sezzjoni 4.8 u 5.3).
English: Table 4
Maltese: 4-il darba
English: − HIV-1 integrase inhibitor (e.g. raltegravir);
Maltese: Inibitur tal- Integrase Raltegravir
English: Virologic Response of Study Subjects at Week 48 Study 802 QD
Maltese: Tabella 4 Rispons Viroloġiku tal-Individwi tal-Istudju f'Ġimgħa 48, Studju 802 QD
English: Most tyrosine kinase inhibitors such as dasatinib and nilotinib, also vincristine and vinblastine:
Maltese: Il-biċċa l-kbira ta' inibituri ta' tyrosine kinase bħal dasatinib u nilotinib, kif ukoll vincristine u vinblastine:
English: Mean baseline CD4+ T-cell count was 838 cells/mm3 and mean baseline plasma HIV-1 RNA was 4.7 log10 copies/ml.
Maltese: Il-medja linja bażi fl-għadd ta' ċelluli CD4+ T-cell kienet 838 ċelluli/mm3 u l-medja linja bażi plazma HIV-1 RNA kien 4.7 log10 kopji/ml.
English: Mean baseline CD4+ T-cell count was 259 cells/mm3 (range: 2 to 949 cells/mm3) and mean baseline plasma HIV-1 RNA was 4.9 log10 copies/ml (range: 2.6 to 6.8 log10 copies/ml).
Maltese: Il-linja bażi medja tal-għadd ta' CD4+ T-cell kien ta' 259 ċelloli/mm3 (bejn 2 sa 949 cellola log10 kopji/ml) u l-linja bażi medja ta' HIV1 RNA fil-plażma kienet ta' 4.9 log10 kopji/ml (minn: 2.6 sa 6.8 log10 kopji/ml).
English: Experienced patients received nevirapine plus up to two nucleoside reverse transcriptase inhibitors.
Maltese: Pazjenti novizzi ingħataw inibituri nucleoside reverse transcriptase.
English: Lopinavir: AUC: ↔ Cmin: ↓ 11% Cmax: ↔
Maltese: AUC: ↔ Cmin: ↓ 11% Cmax: ↔
English: Mean baseline CD4+ T-cell count was 216 cells/mm3 (range: 20 to 775 cells/mm3) and mean baseline plasma HIV-1 RNA was 5.0 log10 copies/ml (range: 1.7 to 7.0 log10 copies/ml).
Maltese: Il-medja tal-għadd ta ' ċelluli T CD4+ fil-linja bażi kien ta ' 216 ċellula/mm3 (medda: 20 sa 775 ċellula/mm3) l-medja fil-linja bazi tal-HIV-1 RNA fil-plażma 5.0 log10 kopja/ml (medda: 1.7 sa 7.0 log10 kopji/ml).
English: − upper respiratory tract infection.
Maltese: Infezzjoni tal- apparat respiratorju ta' fuq
English: Lopinavir/Ritonavir Mylan 400/100 mg + ritonavir 300 mg) twice daily has allowed compensating for the CYP 3A4 inducer effect of rifampicin.
Maltese: Aġġustamet fid-doża ta' Lopinavir/Ritonavir Mylan 400 mg/400 mg (jiġifieri Lopinavir/Ritonavir Mylan 400/100 mg + ritonavir 300 mg) darbtejn kuljum ikkumpensa għall-effett ta' rifamficin li jinduċi CYP 3A4.
English: Lopinavir: AUC: ↔ Cmin: ↓ 20% Cmax: ↔
Maltese: AUC: ↔ Cmin: ↓ 20% Cmax: ↔
English: Tissue distribution studies conducted in the rat did not suggest significant cardiac retention of the active substance; 72-hour AUC in heart was approximately 50% of measured plasma AUC.
Maltese: Studji dwar id-distribuzzjoni tat-tessuti li saru fuq ilfar, ma' issuġġerewx żamma kardijaka sinifikanti tas-sustanza attiva; 72 siegħa AUC fil-qalb kienet bejn wieħed u ieħor 50% tal-plażma AUC imkejla.
English: Plasma concentrations of lopinavir were measured over four 12-hour periods during second trimester (20-24 weeks gestation), third trimester before dose increase (30 weeks gestation), third trimester after dose increase (32 weeks gestation), and at 8 weeks post-partum.
Maltese: Ilkonċentrazzjonijiet ta 'lopinavir fil-plażma tkejlu fuq erba 'perjodi ta '12-il siegħa matul it-tieni trimestru (20-24 ġimgħa ta 'tqala), it-tielet trimestru qabel iż-żieda fid-doża (30 ġimgħa ta 'tqala), ittielet trimestru wara ż-żieda fid-doża (32 ġimgħa ta 'tqala), u 8 ġimgħat wara l-ħlas.
English: The effective (peak to trough) half-life of lopinavir over a 12 hour dosing interval averaged 5 - 6 hours, and the apparent oral clearance (CL/F) of lopinavir is 6 to 7 l /h.
Maltese: Il-half-life effettiva ta' lopinavir (millmassimu sal-minimu) matul intervall ta' dożaġġ ta' 12 -il siegħa, kellu medja ta' 5 - 6 siegħat, u ttneħħija orali evidenti (CL/F) ta' lopinavir hi minn 6 sa 7 l/siegħa.
English: Increased plasma concentrations of paritaprevir; thereby, increasing the risk of alanine transaminase (ALT) elevations (see section 4.5).
Maltese: Żieda fil-konċentrazzjonijiet ta' paritaprevir fil-plażma; b'hekk, jiżdied irriskju ta' żidiet ta ' alanine transaminase (ALT) (ara sezzjoni 4.5).
English: The mean changes from baseline in PR interval ranged from 11.6 ms to 24.4 ms in the
Maltese: Fl-intervall ta' 12-il siegħa ta' wara li ngħatat id-doża, it-tibdil medju mil-linja bażi fl-intervall PR varja minn 11.6 ms sa 24.4 ms.
English: Cmax: ↑ 6-fold Initially, bosentan Cmin: ↑ by approximately 48-fold.
Maltese: Fil-bidu, bosentan Cmin : ↑ bejn wieħed u ieħor b'48 darba.
English: In the absence of human serum, the mean IC50 of lopinavir was 6.5 nM against several HIV-1 clinical isolates.
Maltese: Fl-assenza ta' serum uman, lIC50 medja ta' lopinavir kienet ta' 6.5 nM kontra ħafna iżolati kliniċi ta' HIV-1.
English: The in vitro antiviral activity of lopinavir against laboratory and clinical HIV strains was evaluated in acutely infected lymphoblastic cell lines and peripheral blood lymphocytes, respectively.
Maltese: Attività antivirali in vitro L-attività antivirali in vitro ta' lopinavir kontra razez ta' l-HIV tal-laboratorju u kliniċi, kienet evalwata f'linji ta' ċelloli limfoblastiċi u limfoċiti tad-demm periferali infettati b'mod akut, rispettivament.
English: Particular caution must be used when prescribing lopinavir/ritonavir and medicinal products known to induce QT interval prolongation such as: chlorpheniramine, quinidine, erythromycin, clarithromycin.
Maltese: Għandha tiġi eżerċitata kawtiela partikolari meta lopinavir/ritonavir jkun qiegħed jingħata minn tabib flimkien ma' prodotti mediċinali oħra magħrufa li jtawlu l-intervall QT, bħal: chlorpheniramine, quinidine, erythromycin, clarithromycin.
English: A more pronounced effect on DM-6705 exposure may be observed during prolonged co-administration with lopinavir/ritonavir.
Maltese: Effett aktar qawwi fuq lesponiment ta' DM 6705 jista' jiġi osservat waqt koamministrazzjoni prolongata ma' lopinavir/ritonavir.
English: Study M05-730 was a randomised, open-label, multicentre trial comparing treatment with lopinavir/ritonavir 800/200 mg once daily plus tenofovir DF and emtricitabine versus lopinavir/ritonavir 400/100 mg twice daily plus tenofovir DF and emtricitabine in 664 antiretroviral treatment-naïve patients.
Maltese: Studju M05-730 kien prova li fiha l-parteċipanti ntgħażlu b'mod każwali, open-label, multiċentrika, li qabbel il-kura b'lopinavir/ritonavir 800/200 mg darba kuljum flimkien ma ' tenofovir DF u emtricitabine, kontra lopinavir/ritonavir 400/100 mg darbtejn kuljum flimkien ma ' tenofovir DF u emtricitabine f'664 pazjent li qatt ma rċivew kura antiretrovirali fil-passat.
English: Steady-state concentrations was moderately decreased due to CYP2C9 and CYP2C19 induction by lopinavir/ritonavir.
Maltese: Minħabba li lopinavir/ritonavir jinduċi CYP2C9 u CYP2C19, kien hemm tnaqqis moderat filkonċentrazzjonijiet fissi.
English: Mean baseline CD4+ T-cell count was 254 cells/mm3 (range: 4 to 952 cells/mm3) and mean baseline plasma HIV-1 RNA was 4.3 log10 copies/ml (range: 1.7 to 6.6 log10 copies/ml).
Maltese: Il-medja tal-għadd ta ' ċelluli T CD4+ fil-linja bażi kien ta ' 254 ċellula/mm3 (medda: 4 sa 952 ċellula/mm3) l-medja fil-linja bazi tal-HIV-1 RNA fil-plażma 4.3 log10 kopja/ml (medda: 1.7 sa 6.6 log10 kopji/ml).
English: Patients were randomised in a 1:1 ratio to receive either lopinavir/ritonavir 800/200 mg once daily (n = 333) or lopinavir/ritonavir 400/100 mg twice daily (n = 331).
Maltese: Il-pazjenti ntgħażlu b'mod każwali fi proporzjon ta ' 1:1 biex jirċievu jew lopinavir/ritonavir 800/200 mg darba kuljum (n = 333) jew lopinavir/ritonavir 400/100 mg darbtejn kuljum (n = 331).
English: BATCH NUMBER Batch/Lot
Maltese: NUMRU TAL-LOTT Lot
English: Pancreatitis1, vomiting, gastrooesophageal reflux disease, gastroenteritis and colitis, abdominal pain (upper and lower), abdominal distension, dyspepsia, haemorrhoids, flatulence Uncommon Gastrointestinal haemorrhage including gastrointestinal ulcer, duodenitis, gastritis and rectal haemorrhage, stomatitis and oral ulcers, faecal incontinence, constipation, dry mouth
Maltese: Emorraġija gastrointestinali li tinkludi ulċerazzjoni gastrointestinali, duodenite, gastrite u emorraġija min wara, stomatite u ulċerazzjoni fil-ħalq, inkontinenza ta' l-iskart tal-ġisem, konstipazzjoni, nixfa fil-ħalq
English: Patients were randomised to either 230 mg lopinavir/57.5 mg ritonavir per m2 or 300 mg lopinavir/75 mg ritonavir per m2. Naïve patients also received nucleoside reverse transcriptase inhibitors.
Maltese: Pazjenti randomi kienu mogħtija 230 mg lopinavir/57.5 mg ritonavir kull m2 jew 300 mg lopinavir/75 mg ritonavir kull m2.
English: CLINICAL PARTICULARS
Maltese: Rizultati kliniċi
English: The 230/57.5 mg/m2 twice daily regimen without nevirapine and the 300/75 mg/m2 twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen without nevirapine.
Maltese: Il- 230/57.5 mg/m2 dożaġġ darbtejn kuljum mingħajr nevirapine u t- 300/75 mg/m2 dożaġġ darbtejn kuljum b'nevirapine pprovdew konċentrazzjonijiet tal-plażma ta' lopinavir simili għal dawk ottenuti f'pazjenti adulti li kienu qed jirċievu 400/100 mg dożaġġ darbtejn kuljum mingħajr nevirapine.
English: Bedaquiline: AUC: ↑ 22% Cmax: ↔
Maltese: AUC: ↑ 22% Cmax: ↔
English: Increased plasma concentrations of colchicine.
Maltese: Żieda fil-konċentrazjonijiet fil-plażma ta' colchicine.
English: Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets OPA/Al/PVC-aluminium blister pack.
Maltese: Lopinavir/Ritonavir Mylan 200 mg/50 mg pilloli miksija b'rita Pakkett bil-folji tal-OPA/Al/PVC-aluminium.
English: Multipack: 60 (2 cartons of 30) Film-coated tablets Multipack: 60x1 (2 cartons of 30x1) Film-coated tablets
Maltese: (2 kartuni ta '30) Pillola miksija b'rita Pakkett multiplu: 60x1 (2 kartuni ta '30x1)
English: Concomitant administration of elbasvir/grazoprevir with Lopinavir/Ritonavir Mylan is contraindicated (see section 4.3).
Maltese: L-għoti fl-istess ħin ta' elbasvir/grazoprevir ma' Lopinavir/Ritonavir Mylan hu kontraindikat (ara sezzjoni 4.3).
English: If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
Maltese: Jekk tkun indikata kura b'impeditur HMG-CoA reductase, pravastatin jew fluvastatin huma rrakkomandati (ara sezzjoni 4.5).
English: or
Maltese: E
English: - Multipack containing 360 (3 bottles of 120) film-coated tablets.
Maltese: - Pakkett multiplu li jkun fih 360 (3 fliexken ta' 120) pillola miksija b'rita.
English: - Multipacks containing 120, 120x1 (4 cartons of 30 or 30x1) or 360 (12 cartons of 30) film-coated tablets.
Maltese: - Pakketti multipli li jkun fihom 120, 120x1 (4 kartuni ta' 30 jew 30x1) jew 360 (12-il kartuna ta' 30) pillola miksija b'rita.
English: − The usual adult dose is 400 mg/100 mg twice a day i.e. every 12 hours, in combination with other antiHIV medicines.
Maltese: - Id-doża li ssoltu tingħata għall-adulti hija 400 mg/100 mg darbtejn kuljum, jiġifieri kull 12 -il siegħa, flimkien ma' mediċini oħra għal kontra l-HIV.
English: HIV RNA < 50 copies/ml*† Mean increase from baseline in CD4+ T-cell count (cells/mm3) 207 * intent to treat analysis where patients with missing values are considered virologic failures † p<0.001
Maltese: Żieda medja mill-lija bażi fl-għadd ta' CD4+ T-cell (ċelloli/mm3) * bl-intenzjoni li tkun trattata l-analiżi fejn pazjenti b'valuri nieqsa huma kkunsidrati fallimenti viroloġiċi † p< 0.001
English: AUC: ↑ 5.9-fold Cmax: ↑ 4.7-fold Due to CYP3A inhibition by lopinavir/ritonavir.
Maltese: AUC: ↑ 5.9-darbiet Cmax: ↑ 4.7-darbiet Minħabba li lopinavir/ritonavir jimpedixxi CYP3A.
English: Adverse reactions from clinical trials and post-marketing experience in adult and paediatric patients:
Maltese: Reazzjonijiet avversi min studji kliniċi u esperjenza adulti u pedjatriċi wara t-tqegħid fis-suq:
English: Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets OPA/Al/PVC-aluminium blister pack.
Maltese: Lopinavir/Ritonavir Mylan 100 mg/25 mg pilloli miksija b'rita Pakkett bil-folji tal-OPA/Al/PVC-aluminium.
English: AUC: ↑ 2.71-fold Cmax: ↑ 1.87-fold C24: ↑ 3.58-fold
Maltese: AUC: ↑ 2.71 darbiet Cmax: ↑ 1.87 darbiet
English: − vertigo (spinning feeling);
Maltese: Popolazzjoni pedjatrika (sentejn u fuqhom)
English: Clinical recommendation concerning co-administration with Lopinavir/Ritonavir Mylan
Maltese: Kif taħżen Lopinavir/Ritonavir Mylan
English: The adequate dosing may be achieved with the two available strengths of lopinavir/ritonavir tablets: 100/25 mg and 200/50 mg.*
Maltese: Il-dożaġġ adegwat jista 'jinkiseb biż-żewġ qawwiet disponibbli talpilloli lopinavir/ritonavir: 100/25 mg u 200/50 mg.*
English: Co-administration of increased doses of fosamprenavir (1400 mg BID) with lopinavir/ritonavir (533/133 mg BID) to protease inhibitor-experienced patients resulted in a higher incidence of gastrointestinal adverse events and elevations in triglycerides with the combination regimen without increases in virological efficacy, when compared with standard doses of fosamprenavir/ritonavir.
Maltese: Meta mqabbel ma' dożi standard ta' fosamprenavir/ritonavir, lgħoti ta' dożi miżjuda ta' fosamprenavir (1400 mg BID) flimkien ma' lopinavir/ritonavir (533/133 mg BID) lil pazjenti li diġà kienu ngħataw inibituri talprotease wassal għal inċidenza akbar ta' effetti avversi gastrointestinali u żidiet fit-trigliċeridi mar-reġimen li ngħata miegħu mingħajr ma kien hemm żidiet fleffikaċja viroloġika.
English: Lopinavir provides the antiviral activity of lopinavir/ritonavir.
Maltese: - Is-sustanzi attivi huma lopinavir u ritonavir.
English: AUC: ↑ 2.17-fold Cmax: ↑ 2.04-fold Ctrough: ↑ 2.36-fold (inhibition of CYP3A/efflux transporters)
Maltese: AUC: ↑ 2.17 darbiet Cmax: ↑ 2.04 darbiet Ctrough: ↑ 2.36 darbiet
English: It is not recommended to coadminister Lopinavir/Ritonavir Mylan and boceprevir.
Maltese: Mhux rakkomandat li jiġu koamministrati Lopinavir/Ritonavir Mylan u boceprevir.
English: (combinations of mechanisms including CYP3A inhibition)
Maltese: (kombinazzjonijiet ta' mekkaniżmi li jinkludu inibizzjoni ta' CYP3A)
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jiroveci pneumonia.
Maltese: Eżempji relevati huma retinite kkawżata minn cytomegalovirus, infezzjonijiet generalised u/jew infezzjonijiet fokali ikkawżati minn mycobacteria, u pnewmonja kkawżata minn Pneumocystis jiroveci.
English: Anticonvulsants Phenytoin
Maltese: Mediċini għal kontra l-konvulżjoni Phenytoin
English: Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets Each film-coated tablet contains 100 mg of lopinavir co-formulated with 25 mg of ritonavir as a pharmacokinetic enhancer.
Maltese: Lopinavir/Ritonavir Mylan 100 mg/25 mg pilloli miksija b'rita Kull pillola miksija b'rita fiha 100 mg ta ' lopinavir koformulata b'25 mg ta ' ritonavir bħala enhancer farmakokinetiku.
English: In an open-label pharmacokinetic study, 12 HIV-infected pregnant women who were less than 20 weeks of gestation and on combination antiretroviral therapy initially received lopinavir/ritonavir 400 mg/100 mg (two 200/50 mg tablets) twice daily up to a gestational age of 30 weeks.
Maltese: Fi studju farmakokinetiku open-label, 12-il mara tqila infettati bl-HIV li kellhom tqala ta 'inqas minn 20 ġimgħa u li kienu fuq terapija antiretrovirali kombinata, inizjalment irċivew lopinavir/ritonavir 400 mg/100 mg (żewġ pilloli ta' 200/50 mg) darbtejn kuljum saż-żmien tat-tqala ta '30 ġimgħa.
English: HDPE bottle with white opaque polypropylene screw cap with aluminium induction sealing liner wad and desiccant.
Maltese: Flixkun tal-HDPE b'għatu bil-kamini opak tal-polypropylene, ta ' lewn abjad, b'aluminium induction sealing liner wad u dessikant.
English: Increased plasma concentrations of fusidic acid.
Maltese: Żieda fil-konċentrazzjoni fil-plażma talfusidic acid.
English: At steady state, lopinavir protein binding remains constant over the range of observed concentrations after 400/100 mg lopinavir/ritonavir twice daily, and is similar between healthy volunteers and HIV-positive patients.
Maltese: Fi stat fiss, it-tagħqid ta' lopinavir mal-proteina jibqa' kostanti fuq il-medda ta' konċentrazzjoni osservata wara t-teħid ta' 400/100 mg lopinavir/ritonavir darbtejn kuljum, u dan huwa simili bejn volontiera b'saħħithom u pazjenti li huma pożittivi għall-HIV.
English: Other medicines and Lopinavir/Ritonavir Mylan
Maltese: Mediċini oħra u Lopinavir/Ritonavir Mylan
English: Raltegravir: AUC: ↔ Cmax: ↔ C12 : ↓ 30%
Maltese: AUC: ↔ Cmax: ↔ C12: ↓ 30% Lopinavir: ↔
English: − anticancer medicines (e.g. afatinib, ceritinib, ibrutinib, venetoclax most tyrosine kinases inhibitors such as dasatinib and nilotinib, also vincristine and vinblastine);
Maltese: - anti-bijotiċi (eż. rifabutin, rifampicin, clarithromycin); - mediċini għal kontra l-kanċer (eż. afatinib, ceritinib, ibrutinib, venetoclax, il-biċċa l-kbira ta'
English: Once-daily dosing: the pharmacokinetics of once daily lopinavir/ritonavir have been evaluated in HIVinfected subjects naïve to antiretroviral treatment.
Maltese: Fit-tabella t'hawn taħt hawn imniżżla l-interazzjonijiet magħrufa u dawk teoretiċi ta' lopinavir/ritonavir ma' ċerti prodotti mediċinali antiretrovirali u oħrajn li m'humiex antiretrovirali.
English: Through Week 48, genotypic resistance testing results were available from 75 patients in the QD group and 75 patients in the BID group who had incomplete virologic response.
Maltese: Matul Ġimgħa 48, ir-riżultati tal-ittestjar għal reżistenza ġenotipika kienu disponibbli minn 75 pazjent fil-grupp QD (darba kuljum) u minn 75 pazjent fil-grupp BID (darbtejn kuljum) li kellhom rispons viroloġiku mhux komplut.
English: Strong CYP3A4 inhibitors such as protease inhibitors may increase bedaquiline exposure which could potentially increase the risk of bedaquiline related adverse reactions.
Maltese: Inibituri qawwija ta' CYP3A4 bħal inibituri tal-protease jistgħu jżidu l-espożizzjoni ta' bedaquiline li potenzjalment tista' żżid ir-riskju ta' reazzjonijiet avversi relatati ma' bedaquiline.
English: 3rd Trimester n =
Maltese: 3et Trimestru n = 23*
English: It is not recommended to coadminister Lopinavir/Ritonavir Mylan and telaprevir.
Maltese: Mhux rakkomandat li jiġu koamministrati Lopinavir/Ritonavir Mylan u telaprevir.
English: Concentrations may be reduced due to induction of CYP3A by the herbal preparation St John's wort.
Maltese: Minħabba li l-preparazzjoni talħxejjex tal-fexfiex tar-raba' (St John's Wort) tinduċi CYP3A, jista' jkun hemm tnaqqis filkonċentrazzjonijiet.
English: Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these agents with Lopinavir/Ritonavir Mylan is contraindicated (see section 4.3).
Maltese: HMG-CoA reductase jistgħu jikkawżaw mijopatija, inkluż rabdomilożi, it-taħlit ta' dawn laġenti flimkien ma' Lopinavir/Ritonavir Mylan huwa kontro-indikat (ara sezzjoni 4.3).
English: Multiple dosing with 400/100 mg lopinavir/ritonavir twice daily for 2 weeks and without meal restriction produced a mean ± SD lopinavir peak plasma concentration (Cmax) of 12.3 ± 5.4 μg/ml, occurring approximately 4 hours after administration.
Maltese: Assorbiment Dużaġġ multiplu b'400/100 mg lopinavir/ritonavir darbtejn kuljum għal ġimgħatejn u mingħajr restrizzjoni fuq l-ikel, ipproduċa  SD ta' l-ogħla konċentrazzjoni fil-plażma ta' lopinavir (Cmax) medja ta' 12.3  5.4 g/ml, li ntlaħqet bejn wieħed u ieħor 4 siegħat wara li ġie meħud id-dożaġġ.
English: AUC: ↓ 54% Cmax: ↓ 53% Cmin: ↓ 52%
Maltese: AUC: ↓ 54% Cmax: ↓ 53% Cmin: ↓ 52% Lopinavir: ↔
English: The mean steady-state trough concentration prior to the morning dose was 8.1 ± 5.7 μg/ml.
Maltese: Ilkonċentrazzjoni minimali medja fissa qabel id-doża ta' filgħodu kienet ta' 8.1  5.7 g/ml.
English: A more pronounced effect on bedaquiline plasma exposures may be observed during prolonged co-administration with lopinavir/ritonavir.
Maltese: Effett aktar evidenti fuq esponimenti ta' bedaquiline filplażma jista' jiġi osservat waqt ko-amministrazzjoni prolongata ma' lopinavir/ritonavir.
English: In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Maltese: F'pazjenti infettati bl-HIV u li kellhom nuqqas serju ta' immunita meta inbdiet kura b' terapija antiretrovirali kkombinata (CART), jista jkun hemm reazzjoni infjammatorja għal infezzjoni li ma tidhirx jew li hi opportunistika fil-post.
English: They were randomised in a 1:1 ratio to receive either lopinavir/ritonavir 800/200 mg once daily (n = 300) or lopinavir/ritonavir 400/100 mg twice daily (n = 299).
Maltese: Huma ntgħażlu b'mod każwali fi proporzjon ta ' 1:1 biex jirċievu jew lopinavir/ritonavir 800/200 mg darba kuljum (n = 300) jew lopinavir/ritonavir 400/100 mg darbtejn kuljum (n = 299).
English: Patients were administered at least two nucleoside/nucleotide reverse transcriptase inhibitors selected by the investigator.
Maltese: Ilpazjenti ngħataw mill-inqas żewġ inibituri ta'nucleoside/nucleotide reverse transcriptase magħżula millinvestigatur.